Pharmacologic Therapy for HIV-Associated Lipodystrophy

Annals of Pharmacotherapy

Volumn 38, Issue 3, 2004, Pages 448-457

  Benavides, Sandra ^a,b   Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

Author keywords

Growth hormone; HIV; Lipodystrophy; Metformin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANABOLIC AGENT; CARNITINE; GEMFIBROZIL; HUMAN GROWTH HORMONE; LEPTIN; METFORMIN; NANDROLONE DECANOATE; OXYMETHOLONE; PIOGLITAZONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; TESTOSTERONE; TROGLITAZONE;

ABDOMINAL CRAMP; ABSTRACT REPORT; ARTHRALGIA; ARTICLE; BODY FAT; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DETERIORATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ESTHETICS; FACE EDEMA; FLUSHING; GASTROINTESTINAL SYMPTOM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; JOINT STIFFNESS; LACTIC ACIDOSIS; LEG EDEMA; LIVER TOXICITY; LYMPHOMA; MEDLINE; METABOLIC DISORDER; MUSCLE CRAMP; MYALGIA; NAUSEA; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SIDE EFFECT; STREPTOCOCCUS INFECTION; SUBCUTANEOUS FAT; VOMITING;

ADIPOSE TISSUE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMAN GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 1242338975     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D081     Document Type: Review

References (53)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Heath KV, Montaner JS, Bondy G, Singer J, O'Shaughnessy MV, Hogg RS. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets 2003;4:13-22.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(suppl):F51-8.
5. Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 2002;162:2621-8.
6. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
7. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000;31:1482-7.
8. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-35.
9. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
10. Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf 2001;24:157-66.
11. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquit Immune Defic Syndr 2002;31:257-75.
12. Parker K. Pituitary hormones and their hypothalamic releasing factors. In: Goodman LS, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1541-62.
13. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-803.
14. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001;86:504-10.
15. Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART (letter). AIDS 1999;13:2479-81.
16. Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann Intern Med 1999;131:313-4.
17. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103.
18. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001;86:3480-7.
19. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquit Immune Defic Syndr 2002;30:379-91.
20. Kotler D, Thompson M, Grunfeld C, Testa M, Turner R, Gertner J, et al. Growth hormone (Serostimreg) effectively reduces visceral adipose tissue (VAT) accumulation and non-HDL cholesterol (abstract LbOr18). Presented at: XIV International AIDS Conference, Barcelona, July 7-12, 2002.
21. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999;13:1000-2.
22. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-7.
23. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-5.
24. Martinez E, Domingo P, Perez-Cuevas JB, Arroyo JA, Buira E, Milinkovic A, et al. A randomized double-blind, placebo-controlled, comparative study on the effects of metformin or gemfibrozin in lipodystrophic HIV-1-infected patients receiving protease inhibitors (PI) (abstract 702-T). Presented at: 9th Annual Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002.
25. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquit Immune Defic Syndr 2002;31:163-70.
26. Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003;17:770-2.
27. Mauss S, Schmutz G. L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Med 2001;2:59-60.
28. Gold J, Batterham M. Nandrolone decanoate: use in HIV-associated lipodystrophy syndrome: a pilot study (letter). Int J STD AIDS 1999;10:558.
29. Hengge UR, Stocks K, Unger S, Faulkner S, Goos M, Dudley R. Randomized Phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy (abstract 705-T). Presented at: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002.
30. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002:346:570-8.
31. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
32. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-23.
33. Harrison LC, Martin FI, Melick RA. Correlation between insulin receptor binding in isolated fat cells and insulin sensitivity in obese human subjects. J Clin Invest 1976;58:1435-41.
34. Package insert. Glucophage (metformin). Princeton, NJ: Bristol-Myers Squibb, April 2003.
35. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33.
36. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquit Immune Defic Syndr 2002;29:117-21.
37. McComsey G. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Rev 2002;4:140-7.
38. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55.
39. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53.
40. Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy (letter). Clin Infect Dis 2003;37:315-6.
41. Package insert. Avandia (rosiglitazone). Research Triangle Park, NC: GlaxoSmithKline, March 2003.
42. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
43. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-88.
44. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133:263-74.
45. Kelly GS. L-Carnitine: therapeutic applications of a conditionally-essential amino acid. Altern Med Rev 1998;3:345-60.
46. Patrick L. Nutrients and HIV: part three-N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine. Altern Med Rev 2000;5:290-305.
47. De Simone C, Tzantzoglou S, Jirillo E, Marzo A, Vullo V, Martelli EA. L-carnitine deficiency in AIDS patients. AIDS 1992;6:203-5.
48. Hiipakka RA. Androgenic and anabolic steroids and antagonists. In: Hardman JG, Le L, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:851-64.
49. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998;12:441-51.
50. Della-Fera MA, Qian H, Baile CA. Adipocyte apoptosis in the regulation of body fat mass by leptin. Diabetes Obes Metab 2001;3:299-310.
51. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26:1407-33.
52. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab 2000;11:410-6.
53. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002;31:514-20.